Expression of dual Nucleotides/Cysteinyl‐Leukotrienes Receptor GPR17 in early trafficking of cardiac stromal cells after myocardial infarction. Issue 9 (7th June 2014)

• Record Type: Journal Article
• Authors: Cosentino, Simona; Castiglioni, Laura; Colazzo, Francesca; Nobili, Elena; Tremoli, Elena; Rosa, Patrizia; Abbracchio, Maria P.; Sironi, Luigi; Pesce, Maurizio
• Is Part Of: Journal of cellular and molecular medicine. Volume 18:Issue 9(2014)
• Page Start: 1785
• Page End: 1796
• Publication Date: 2014-06-07
• Subjects: Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.12305
• Languages: English
• ISSNs: 1582-1838

Abstract

<abstract abstract-type="main" id="jcmm12305-abs-0001"> <title>Abstract</title> <p>GPR17 is a G<sub>i</sub>‐coupled dual receptor activated by uracil‐nucleotides and cysteinyl‐leukotrienes. These mediators are massively released into hypoxic tissues. In the normal heart, GPR17 expression has been reported. By contrast, its role in myocardial ischaemia has not yet been assessed. In the present report, the expression of GPR17 was investigated in mice before and at early stages after myocardial infarction by using immunofluorescence, flow cytometry and RT‐PCR. Before induction of ischaemia, results indicated the presence of the receptor in a population of stromal cells expressing the stem‐cell antigen‐1 (Sca‐1). At early stages after ligation of the coronary artery, the receptor was expressed in Sca‐1<sup>+</sup> cells, and cells stained with Isolectin‐B4 and anti‐CD45 antibody. GPR17<sup>+</sup> cells also expressed mesenchymal marker CD44. GPR17 function was investigated <italic>in vitro</italic> in a Sca‐1<sup>+</sup>/CD31<sup>−</sup> cell line derived from normal hearts. These experiments showed a migratory function of the receptor by treatment with UDP‐glucose and leukotriene LTD4, two GPR17 pharmacological agonists. The GPR17 function was finally assessed <italic>in vivo</italic> by treating infarcted mice with Cangrelor, a pharmacological receptor antagonist, which, at least in part, inhibited early recruitment of GPR17<sup>+</sup> and CD45<sup>+</sup> cells. These findings suggest a regulation of heart‐resident mesenchymal cells and blood‐borne cellular species recruitment following myocardial infarction, orchestrated by GPR17.</p> </abstract>